APSIPA Transactions on Signal and Information Processing > Vol 12 > Issue 5

ExAD-GNN: Explainable Graph Neural Network for Alzheimer’s Disease State Prediction from Single-cell Data

Ziheng Duan, Department of Computer Science, University of California, Irvine, USA, Cheyu Lee, Department of Computer Science, University of California, Irvine, USA, Jing Zhang, Department of Computer Science, University of California, Irvine, USA, zhang.jing@uci.edu
 
Suggested Citation
Ziheng Duan, Cheyu Lee and Jing Zhang (2023), "ExAD-GNN: Explainable Graph Neural Network for Alzheimer’s Disease State Prediction from Single-cell Data", APSIPA Transactions on Signal and Information Processing: Vol. 12: No. 5, e201. http://dx.doi.org/10.1561/116.00000239

Publication Date: 12 Oct 2023
© 2023 Z. Duan, C. Lee and J. Zhang
 
Subjects
 

Share

Open Access

This is published under the terms of CC BY-NC.

Downloaded: 393 times

In this article:
Introduction 
Methodology 
Experimental Results 
Discussion and Conclusion 
References 

Abstract

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder with significant impacts on patients and their families. Therefore, accurate and early diagnosis of AD is crucial for improving patient outcomes and developing effective treatments. However, despite advancements in machine learning for AD diagnosis, current methods lack molecular-level insights and completely ignore the heterogeneity in complex human brains, thus potentially masking crucial disease mechanisms. Here, we present ExAD-GNN, an Explainable Graph Neural Network for predicting AD status from single-cell sequencing data. Leveraging K Nearest Neighbours (KNN) graphs derived from the expression profiles of individual cells, ExAD-GNN achieves two primary goals: predicting AD pathology at a cellular level and identifying cell-type-specific marker genes for AD diagnosis through a unique learnable gene importance metric. Extensive benchmarking on large-scale scRNA-seq data with state-of-the-art methods demonstrates ExAD-GNN’s noticeably improved AD prediction accuracy and robustness across various cell types and samples. Furthermore, an extensive ablation study and literature search confirm the majority of top AD risk genes highlighted by our method, demonstrating the effectiveness of ExAD-GNN’s model interpretation scheme. In summary, we develop ExAD-GNN as a publicly available software for the scientific community to gain molecular insights into AD pathology from scRNA-seq data.

DOI:10.1561/116.00000239

Companion

APSIPA Transactions on Signal and Information Processing Special Issue - AI for Healthcare
See the other articles that are part of this special issue.